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STO (p<0.001, all). Combination of these ﬁndings could distinguish
CTO from STO (c-statistics¼0.88 (95% CI¼0.94–0.90),
sensitivity¼83%, speciﬁcity¼77%, positive predictive value (PPV)¼
55%, negative predictive value (NPV)¼93%, p<0.001). Percutaneous
coronary intervention (PCI) was attempted in 342 arteries and was
successful in 279 arteries (82%). CT ﬁndings could predict the un-
successful PCI (c-statistics¼0.70 (0.65–0.75), sensitivity¼63%, specif-
icity¼73%, PPV¼91%, NPV¼31%, p<0.001).
CONCLUSIONS Non-invasive coronary CT angiography could discern
chronic total occlusion from subtotal occlusion, and also could predict
the success of attempted PCI.
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BACKGROUND Previous studies have shown that high and low
platelet reactivity (HPR and LPR respectively) are associated with
adverse events following percutaneous coronary intervention (PCI),
however, therapy windows were not consistent in different studies.
We aimed to determine the optimal cutoff value of platelet reactivity
to prevent major adverse events (MACE) and bleeding in eastern Asian
PCI patients.
METHODS Consecutive 6266 non-emergent PCI patients with aspirin
and clopidogrel therapy were enrolled prospectively in the single-
center, large-volume investigation from January to December 2013.
Platelet reactivity (ADP-induced platelet-ﬁbrin clot strength
[MAADP]) was determined by thrombelastography. MACE and
Bleeding Academic Research Consortium (BARC) classiﬁcation2
bleeding were assessed between different categories of platelet reac-
tivity and Syntax Score (SS).
RESULTS Overall, 475 MACE and 152 major bleeding (BARC grade2)
events were recorded during one year follow-up. With receiver
operating characteristic (ROC) curve, we determined the cutoff values
of MAADP for MACE and major bleeding (45 mm and 34mm, respec-
tively). Then, patients were classiﬁed according to MAADP (>45 mm,
34–45 mm, and <34 mm) and we evaluated the impact of platelet
reactivity on MACE and major bleeding in different Syntax Score
subgroups (SS<15 and SS15) with multivariable Cox survival anal-
ysis. In low SS group, MAADP>45 mm was the predictor of MACE (HR:
2.3; 95%CI: 1.6-5.9), but MAADP<34 mm did not show signiﬁcant
predicting value for major bleeding (HR: 1.3; 95%CI: 0.4-8.1). In high
SS group, MAADP>45 mm was still the predictor of MACE (HR: 2.6;
95%CI: 1.3-6.3), while MAADP<34 mm show signiﬁcant impact on
major bleeding (HR: 1.8; 95%CI: 1.2-4.7).
CONCLUSIONS Platelet reactivity measured by thrombelastography
could predict MACE and major bleeding in elective PCI patients,
especially in those with high SS. Therapy window of anti-platelet
drugs is narrow in eastern Asian population and further studies on
tailored treatment of high-risk patients are needed.
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BACKGROUND Drug-eluting stents (DES) reduce angiographic reste-
nosis and enhance event-free survival compared with bare-metalstents after implantation in coronary arteries. Limitations of current
DES remain stent thrombosis and neo-atherosclerosis related to
impaired healing, and repeat revascularization due to (late-) in-
stent-restenosis. Endothelial repair can be substantially enhanced
by CD34þ endothelial progenitor cells. The Combo stent combines a
CD34þ antibody layer to attract endothelial progenitor cells, and
thus promotes stent healing, with the abluminal release of sirolimus
to prevent neointima formation and restenosis. The aim of this
registry is to evaluate the long term safety and performance of the
abluminal sirolimus coated bio-engineered stent in routine clinical
practice.
METHODS The multicenter, prospective, clinical outcomes after
deployment of the abluminal sirolimus coated bio-engineered stent
post market registry, the REMEDEE Registry, is an international
registry to evaluate outcomes in an all-comers population of patients
undergoing percutaneous coronary intervention with (attempted)
Combo stent placement in the setting of routine clinical care. Base-
line demographic, clinical, and angiographic data, as well as follow-
up data up to ﬁve years will be obtained. Clinical endpoints are
deﬁned as a composite of cardiac death, non-fatal myocardial
infarction (MI) not clearly attributable to a non-target vessel, or
target lesion revascularization (TLR) (percutaneous or by coronary
artery bypass grafting (CABG)) in consecutive patients undergoing
percutaneous coronary intervention with (attempted) Combo stent
placement. All events will be adjudicated by an independent Clinical
Events Committee. Cumulative event rates are estimated by a
Kaplan-Meier model.
RESULTS A total of 1000 patients were included in 9 European sites
between June 2013 and March 2014, of which 30.4% patients pre-
senting with acute coronary syndrome (ACS) (17.8% ST-segment
elevation myocardial infarction). Mean age was 6511 years, 73.9% of
patients are male. 184 (18.4%) patients are diabetic, 25.3% of patients
have had a previous myocardial infarction, 6.8% had previous CABG.
The primary endpoint of one year target lesion failure will be available
at the TCT conference 2015.
CONCLUSIONS This is the ﬁrst multicenter, prospective, non-inter-
ventional trial evaluating the long term clinical outcomes of patients
treated with a Combo stent.
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BACKGROUND The incidence, predictors, and prognostic impact of
post-discharge bleeding (PDB) after percutaneous coronary interven-
tion (PCI) with drug-eluting stent (DES) implantation are unclear. This
study sought to characterize the determinants and consequences of
PDB after PCI.
METHODS The incidence and predictors of clinically relevant
bleeding events occurring within 2 years following hospital
discharge were assessed from the prospective Assessment of Dual
Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) study.
